Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433752 · ClinicalTrials.gov registry record
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
A clinical trial of Multiple Sclerosis and Relapsing Multiple Sclerosis, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT06433752 is a study of Multiple Sclerosis and Relapsing Multiple Sclerosis that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 500 participants, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06433752, a study of Multiple Sclerosis and Relapsing Multiple Sclerosis, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (20)
Colorado
- TG Therapeutics Investigational Trial Site - Aurora
- TG Therapeutics Investigational Trial Site - Basalt
- TG Therapeutics Investigational Trial Site - Colorado Springs
- TG Therapeutics Investigational Trial Site - Denver
- TG Therapeutics Investigational Trial Site - Fort Collins
- TG Therapeutics Investigational Trial Site - Grand Junction
California
- TG Therapeutics Investigational Trial Site - Fresno
- TG Therapeutics Investigational Trial Site - Newport Beach
- TG Therapeutics Investigational Trial Site - Orange
- TG Therapeutics Investigational Trial Site - West Hollywood
Arizona
- TG Therapeutics Investigational Trial Site - Gilbert
- TG Therapeutics Investigational Trial Site - Phoenix
- TG Therapeutics Investigational Trial Site - Scottsdale
Alabama
- TG Therapeutics Investigational Trial Site - Birmingham
- TG Therapeutics Investigational Trial Site - Mobile
Connecticut
- TG Therapeutics Investigational Trial Site - Farmington
- TG Therapeutics Investigational Trial Site - Hartford
Delaware
- TG Therapeutics Investigational Trial Site - Wilmington
District of Columbia
- TG Therapeutics Investigational Trial Site - Washington D.C.
Florida
- TG Therapeutics Investigational Trial Site - Altamonte Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2027-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06433752
The ClinicalTrials.gov registry entry for NCT06433752 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (14% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06433752 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06433752 about?
NCT06433752 is a clinical study titled "A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)". The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
What is the current status of trial NCT06433752?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-07-22. Estimated completion is 2027-07-01.
What conditions does trial NCT06433752 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06433752?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06433752?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06433752 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.